NCT04863339

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of North Carolina, Chapel Hill · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compared to a placebo. To answer this hypothesis, the investigators are conducting a randomized controlled trial in which half of participants will receive TXA and half will receive placebo (saline) in a double blind fashion.

Conditions

• Pituitary Tumor
• Blood Loss
• Surgery

Interventions

Type	Name	Description
DRUG	Tranexamic acid	Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
DRUG	Placebo	Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.

Timeline

• Start date: 2022-03-01
• Primary completion: 2022-04-01
• Completion: 2022-04-01
• First posted: 2021-04-28
• Last updated: 2022-04-05

Regulatory

• FDA-regulated drug study